Surfer_02.jpg
BKGD images Orange1.jpg
Scientific BKGD_01.jpg
BKGD images Blue.jpg
Scientific BKGD_02.jpg
Scientific BKGD_03.jpg
BKGD+images+Blue.jpg
BKGD images Gray.jpg
BKGD images Orange1.jpg
Surfer_02.jpg

New Therapies


SCROLL DOWN

New Therapies


A New Class of Therapies
Based on a Growing Understanding of How the Immune System Works

BKGD images Orange1.jpg

Our Science


Our Science


Modulation of the gut-body network has therapeutic potential in multiple disease areas. We are developing a new class of therapies which are designed to act on immune cells in the gut for effects throughout the body.

Evelo's Therapies


Evelo's Therapies


 

Evelo's therapies are based on two newly appreciated areas of biology

  • The gut is central to human biology and is connected to all parts of the body via the lymphatic system.
  • Microbes have naturally evolved to modulate systemic biology through the gut-body network.

Based on these two central principles of previously underappreciated biology, we are developing a new class of therapies – monoclonal microbials.

 
Scientific BKGD_01.jpg

Monoclonal Microbials


Monoclonal Microbials


 

The gut-body network

The gut is the largest part of the immune system and is a central hub of the body’s network of lymphatic vessels. Immune cells circulate through tissues of the gut via these lymphatic vessels, where they are conditioned by exposure to the contents of the gut. These conditioned immune cells may then impact disease and health at all sites of the body. Our product candidates have the potential to condition immune cells in the gut.
 

Monoclonal microbials

Our product candidates are monoclonal microbials – orally-delivered pharmaceutical compositions of single microbial strains that act through the gut-body network to potentially impact disease. Monoclonal microbials are designed to act directly on immune cells in the gut, independent of the resident microbiome. The action of our product candidates does not require colonization of the gut or changing the resident microbiome.

We have observed in preclinical studies that selected monoclonal microbials can downregulate or upregulate immune responses throughout the body by acting on the gut-body network. We believe that monoclonal microbials exert their effects through interactions with host immune cells as they pass through the gut. Based on our preclinical studies, we believe that our product candidates could significantly improve the treatment of many diseases.

 

Systematic Biology


Systematic Biology


 

Monoclonal microbials are designed to act on the gut-body network to modulate systemic biology

lympatic-system.jpg
  1. Sampling of microbes in the gut by macrophages and dendritic cells
  2. Conditioning of T-cells by dendritic cells and macrophages in the lymph node
  3. Migration of conditioned T-cells throughout the body

Our Portfolio


Our Portfolio


Our Portfolio

We are advancing multiple monoclonal microbial product candidates into clinical studies across oncology and inflammatory diseases. These first-in-human studies are expected to begin in 2018 and to deliver 10 clinical readouts across inflammatory diseases and cancer during 2019 and 2020.

our-portfolio.jpg

Our Platform


Our Platform


Our Platform

We have developed an integrated platform designed to identify individual strains of microbes capable of modulating the immune system by acting on the gut-body network when administered at pharmacologically active doses. We use the process development and formulation capabilities of our platform to develop selected microbes as clinical product candidates.

our-platform.jpg
 
BKGD images Blue.jpg

What Matters


What Matters


We are committed to
dramatically improving healthcare

Monoclonal microbials have the potential to improve upon other approaches to drug discovery and development. The development of monoclonal microbials may improve upon the speed, cost and probability of drug discovery and development. We believe monoclonal microbials may offer new treatment possibilities for patients at all stages of disease.

Scientific BKGD_02.jpg

Patients and Caregivers


Patients and Caregivers


Patients and Caregivers

Evelo is committed to working with patients and physicians to develop new therapies for a wide range of diseases. We expect to begin enrolling patients in clinical trials for certain indications in the near future. For inquiries, please contact us here.

Our Team


Our Team


 

Evelo is led by a team with deep experience

Leadership

  • Simba Gill
    CEO
  • Mark Bodmer
    President of R&D, Chief Scientific Officer
  • William Devaul
    Head of Intellectual Property
  • Michael Garcia-Webb
    Head of People an Operational Excellence
  • Humphrey Gardner
    Chief of Medical Oncology
  • Jennifer Glennon
    Head of Finance and Operations
  • Brian Goodman
    Head of Technology and Innovation
  • Andrea Itano
    Head of Immuno-Inflammatory Diseases
  • Duncan McHale
    Chief Medical Officer
  • Jonathan Poole
    Chief Financial Officer
  • Kareem Reda
    Head of BD & Corporate Strategy
  • Hank Wu
    Head of Data Science
  • Chun Zhang
    Head of Process Development and Manufacturing

Board of Directors

  • Noubar Afeyan
    Chairman
  • Simba Gill
    CEO
  • Professor the Lord Ara Darzi
    Director
  • David Epstein
    Director
  • Theo Melas-Kyriazi
    Director
  • David Perry
    Director
  • Nancy Simonian
    Director

 
Scientific BKGD_03.jpg

Investors


Investors


Founder and Investors

Evelo was founded by Flagship Pioneering. Flagship VentureLabs’ innovators conceived of and developed Evelo’s foundational inventions, leading to the launch of Evelo Biosciences in July 2015. Additional investors in Evelo include, GV (the venture capital arm of Alphabet, Inc.), Celgene, Mayo Clinic and Alexandria Real Estate Equities.

Investor Logos


Investor Logos


BKGD images Gray.jpg

Destination


Destination


The destination for pioneers and adventurers

If you want to join an exceptional team and culture that is committed to changing the world, let us know.

BKGD images Orange1.jpg

Contact


Contact


Contact

620 Memorial Drive | Suite 200 West | Cambridge, MA, 02139 USA

For general inquiries contact:
info@evelobio.com

For media inquiries contact:
media@evelobio.com

For investor inquiries contact:
ir@evelobio.com